<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article229</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/AVERT" style="display:block; margin-bottom:10px;">AVERT Original</a></li>
<h2><strong>AVERT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Apixaban for Thromboprophylaxis in Cancer Patients". The New England Journal of Medicine. 2018. 378:711-719. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In ambulatory patients with cancer at intermediate-to-high risk for venous thromboembolism who are starting chemotherapy, does thromboprophylaxis with apixaban reduce the incidence of venous thromboembolism compared with placebo?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Apixaban significantly reduced the incidence of venous thromboembolism in ambulatory patients with cancer at intermediate-to-high risk who were starting chemotherapy, at the expense of an increased risk of major bleeding episodes.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of this trial's publication, guidelines for thromboprophylaxis in cancer patients were not established based on the findings of this study.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, placebo-controlled, double-blind trial<br/>
N=574 patients<br/>
Randomized 1:1 to receive apixaban or placebo<br/>
Treatment period: 180 days<br/>
Median follow-up: 183 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
-Newly diagnosed cancer or progression after remission<br/>
-Initiating new chemotherapy course<br/>
-Khorana score ≥2<br/>
-Age ≥18 years<br/>
<br/>
Exclusion Criteria<br/>
-Risk factors for significant bleeding<br/>
-Hepatic disease with coagulopathy<br/>
-Certain cancer diagnoses (basal-cell/squamous-cell skin cancer, acute leukemia, or myeloproliferative neoplasm)<br/>
-Planned stem-cell transplantation<br/>
-Life expectancy &lt;6 months<br/>
-Renal insufficiency, platelet count &lt;50,000 per cubic millimeter<br/>
<br/>
Baseline Characteristics<br/>
-Mean age 61 years<br/>
-58.2% women<br/>
-Most common cancers: gynecologic (25.8%), lymphoma (25.3%), and pancreatic (13.6%)<br/>
-22.8% were using antiplatelet or NSAIDs<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
-Apixaban: 2.5 mg twice daily<br/>
-Placebo: identical tablets twice daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
-Venous thromboembolism: 4.2% in apixaban group vs. 10.2% in placebo group (hazard ratio, 0.41; 95% CI, 0.26 to 0.65; P&lt;0.001)<br/>
<br/>
Secondary Outcomes<br/>
-Major bleeding: 3.5% in apixaban group vs. 1.8% in placebo group (hazard ratio, 2.00; 95% CI, 1.01 to 3.95; P=0.046)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
-Limited ability to make definitive conclusions about individual tumor types or chemotherapy regimens based on sample size.<br/>
-Results may be less applicable to patients with significant renal dysfunction.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Canadian Institutes of Health Research and Bristol-Myers Squibb–Pfizer Alliance.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full article can be accessed at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
